Infliximab treatment prevents hyperglycemia and the intensification of hepatic gluconeogenesis in an animal model of high fat diet-induced liver glucose overproduction

Brazilian Archives of Biology and Technology

Karissa Satomi Haida²  Gabriela Bertachini²  Thauany Tavoni²  Márcio Guilhermetti²  Marco Rocha Loures¹  Roberto Barbosa Bazotte² 

[1],Universidade Estadual de Maringá Departamento de Farmacologia e Terapêutica Clínica

关键词: Infliximab;    hyperglycemia;    TNF-alpha;    liver gluconeogenesis;    type 2 diabetes;    mouse;   

DOI  :  10.1590/S1516-89132012000300009

来源: SciELO

【 摘 要 】

The effect of infliximab on gluconeogenesis in an animal model of diet-induced liver glucose overproduction was investigated. The mice were treated with standard diet (SD group) or high fat diet (HFD group). HFD group were randomly divided and treated either with saline (100 µl/dose, ip, twice a day) or infliximab (10 µg in 100 µl saline per dose, ip, twice a day, i.e., 0.5 mg/kg per day). SD group also received saline. The treatment with infliximab or saline started on the first day of the introduction of the HFD and was maintained during two weeks. After this period, the mice were fasted (15 h) and anesthetized. After laparotomy, blood was collected for glucose determination followed by liver perfusion in which L-alanine (5 mM) was used as gluconeogenic substrate. HFD group treated with saline showed higher (p < 0.05) liver glucose production from L-alanine and fasting hyperglycemia. However, these metabolic changes were prevented by infliximab treatment. Therefore, this study suggested that infliximab could prevent the glucose overproduction and hyperglycemia related with glucose intolerance and type 2 diabetes.

【 授权许可】

CC BY-NC   
 All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License